uniQure (NASDAQ:QURE) Sets New 52-Week High - Time to Buy?

Key Points

• The stock price of uniQure N.V. (NASDAQ: QURE) hit a new 52-week high at $42.71 before closing at $38.09, following a trading volume of about 18.6 million shares.
• Equities research analysts have shown bullish sentiment, with a consensus buy rating and price target estimates ranging upwards to $70.00 from HC Wainwright.
• The company reported a quarterly EPS of ($0.69), which exceeds analyst expectations, while also achieving a revenue of $5.26 million compared to forecasts of $5.00 million.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $42.71 and last traded at $38.09, with a volume of 18598206 shares trading hands. The stock had previously closed at $13.66.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on QURE shares. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research note on Friday, September 5th. Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research report on Wednesday, July 30th. Chardan Capital reissued a "buy" rating and set a $35.00 target price on shares of uniQure in a research report on Monday, September 8th. Mizuho raised shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price for the company in a research report on Thursday, August 14th. Finally, Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $37.45.

uniQure Price Performance

The firm's 50 day simple moving average is $15.24 and its two-hundred day simple moving average is $14.09. The firm has a market capitalization of $2.21 billion, a P/E ratio of -10.39 and a beta of 0.14. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. As a group, analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP increased its position in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the period. Nantahala Capital Management LLC increased its position in shares of uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after buying an additional 101,598 shares during the period. Aberdeen Group plc increased its position in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock valued at $38,345,000 after buying an additional 535,163 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of uniQure during the second quarter valued at about $29,217,000. Finally, JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after buying an additional 1,491,486 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.